A phase I/II trial of celecoxib with chemotherapy and radiotherapy in the treatment of patients with locally advanced oesophageal cancer

Investigational New Drugs

Volumn 25, Issue 2, 2007, Pages 123-129

  Dawson, S J ^a   Michael, M ^a   Biagi, J ^a   Foo, K F ^a   Jefford, M ^a,b   Ngan, S Y ^a   Leong, T ^a   Hui, A ^a   Milner, A D ^a   Thomas, R J S ^a   Zalcberg, J R ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Celecoxib; Chemotherapy; Oesophageal cancer; Radiotherapy

Indexed keywords

CELECOXIB; CISPLATIN; FLUOROURACIL;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONFIDENCE INTERVAL; DEHYDRATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPHAGIA; ESOPHAGITIS; ESOPHAGUS CANCER; FATIGUE; FEMALE; FOLLOW UP; HUMAN; KIDNEY DYSFUNCTION; MALE; MAXIMUM TOLERATED DOSE; MULTIMODALITY CANCER THERAPY; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PATIENT COMPLIANCE; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; SURVIVAL RATE; SURVIVAL TIME; UNSPECIFIED SIDE EFFECT;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PYRAZOLES; SULFONAMIDES; SURVIVAL ANALYSIS;

EID: 33845863415     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-006-9016-5     Document Type: Article

References (34)

1. Refaely Y, Krasna MJ (2002) Multimodality therapy for esophageal cancer. Surg Clin North Am 82:729-746
2. Enzinger PC, Mayer RJ (2003) Esophageal cancer. N Engl J Med 349:2241-2252
3. al-Sarraf M, Martz K, Herskovic A et al (1997) Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol 15:277-284
4. Cooper JS, Guo MD, Herskovic A et al (1999) Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. Jama 281:1623-1627
5. Stahl M, Stuschke M, Lehmann N et al (2005) Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 23:2310-2317
6. Walsh TN, Noonan N, Hollywood D et al (1996) A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 335:462-467
7. Berger AC, Farma J, Scott WJ et al (2005) Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol 23:4330-4337
8. Williams CS, Mann M, DuBois RN (1999) The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 18:7908-7916
9. Shamma A, Yamamoto H, Doki Y et al (2000) Up-regulation of cyclooxygenase-2 in squamous carcinogenesis of the esophagus. Clin Cancer Res 6:1229-1238
10. Wilson KT, Fu S, Ramanujam KS, Meltzer SJ (1998) Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res 58:2929-2934
11. Zimmermann KC, Sarbia M, Weber AA et al (1999) Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 59:198-204
12. von Rahden BH, Stein HJ, Puhringer F et al (2005) Coexpression of cyclooxygenases (COX-1, COX-2) and vascular endothelial growth factors (VEGF-A, VEGF-C) in esophageal adenocarcinoma. Cancer Res 65:5038-5044
13. Souza RF, Shewmake K, Beer DG et al (2000) Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res 60:5767-5772
14. Morgan G, Vainio H (1998) Barrett's oesophagus, oesophageal cancer and colon cancer: an explanation of the association and cancer chemopreventive potential of non-steroidal anti-inflammatory drugs. Eur J Cancer Prev 7: 195-199
15. Masferrer JL, Leahy KM, Koki AT et al (2000) Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60:1306-1311
16. Sweeney CJ (2003) Why cyclooxygenase-2 inhibition plus chemotherapy? Am J Clin Oncol 26:S122-S125
17. Ratnasinghe D, Daschner PJ, Anver MR et al (2001) Cyclooxygenase-2, P-glycoprotein-170 and drug resistance; is chemoprevention against multidrug resistance possible? Anticancer Res 21:2141-2147
18. Uchida K, Schneider S, Yochim JM et al (2005) Intratumoral COX-2 gene expression is a predictive factor for colorectal cancer response to fluoropyrimidine-based chemotherapy. Clin Cancer Res 11:3363-3368
19. Kishi K, Petersen S, Petersen C et al (2000) Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res 60:1326-1331
20. Milas L, Kishi K, Hunter N et al (1999) Enhancement of tumor response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme. J Natl Cancer Inst 91:1501-1504
21. Choy H, Milas L (2003) Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rational advance? J Natl Cancer Inst 95:1440-1452
22. Greene FL et al (2002) AJCC cancer staging manual. Springer-Verlay, New York
23. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
24. Bombardier C, Laine L, Reicin A et al (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343:1520-1528, 1522 p following 1528
25. FitzGerald GA, Patrono C (2001) The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 345:433-442
26. Silverstein FE, Faich G, Goldstein JL et al (2000) Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. Jama 284:1247-1255
27. Harris RC Jr (2002) Cyclooxygenase-2 inhibition and renal physiology. Am J Cardiol 89:10D-17D
28. Bresalier RS, Sandler RS, Quan H et al (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352:1092-1102
29. Solomon SD, McMurray JJ, Pfeffer MA et al (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352:1071-1080
30. Mukherjee D, Nissen SE, Topol EJ (2001) Risk of cardiovascular events associated with selective COX-2 inhibitors. Jama 286:954-959
31. Lorenz M, Slaughter HS, Wescott DM et al (1999) Cyclooxygenase-2 is essential for normal recovery from 5-fluorouracil-induced myelotoxicity in mice. Exp Hematol 27:1494-1502
32. Leese PT, Hubbard RC, Karim A et al (2000) Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. J Clin Pharmacol 40:124-132
33. Govindan R, McLeod H, Mantravadi P et al (2004) Cisplatin, fluorouracil, celecoxib, and RT in resectable esophageal cancer: preliminary results. Oncology (Williston Park) 18:18-21
34. Enzinger PC et al (2004) Phase II trial of cisplatin, irinotecan, celecoxib and concurrent radiotherapy followed by surgery for locally advanced esophageal cancer. ASCO GI Symposium